Danaher (NYSE:DHR) Rating Reiterated by Stephens

Stephens restated their overweight rating on shares of Danaher (NYSE:DHR) in a research note published on Wednesday, Benzinga reports. Stephens currently has a $315.00 price objective on the conglomerate’s stock.

DHR has been the subject of several other reports. Leerink Partners lifted their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Stifel Nicolaus boosted their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday. TD Cowen raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. UBS Group reduced their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Bank of America lifted their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $287.28.

Danaher Stock Down 1.0 %

Shares of NYSE:DHR opened at $245.41 on Wednesday. The firm has a market capitalization of $181.77 billion, a P/E ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a 50 day moving average price of $270.00 and a 200-day moving average price of $260.34. Danaher has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.02 EPS. As a group, equities research analysts anticipate that Danaher will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Activity at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Linda Filler sold 3,928 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the sale, the director now owns 41,149 shares of the company’s stock, valued at $11,501,145.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,059 shares of company stock worth $8,400,897 in the last 90 days. 11.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Danaher

A number of large investors have recently bought and sold shares of DHR. Good Life Advisors LLC bought a new position in shares of Danaher in the 3rd quarter worth $217,000. Oak Thistle LLC purchased a new position in Danaher in the second quarter valued at about $363,000. Norden Group LLC bought a new position in Danaher in the first quarter worth about $4,151,000. Duality Advisers LP bought a new stake in shares of Danaher in the 1st quarter valued at about $5,573,000. Finally, Investment Research & Advisory Group Inc. bought a new position in shares of Danaher during the 1st quarter worth approximately $1,186,000. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.